Bicycle Therapeutics plc (NASDAQ:BCYC) CTO Michael Skynner Sells 3,287 Shares

Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) CTO Michael Skynner sold 3,287 shares of the business's stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total value of $46,313.83. Following the transaction, the chief technology officer now directly owns 124,658 shares in the company, valued at approximately $1,756,431.22. This represents a 2.57 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Bicycle Therapeutics Trading Down 0.1 %

Shares of NASDAQ BCYC traded down $0.01 during trading hours on Monday, reaching $14.88. The stock had a trading volume of 289,310 shares, compared to its average volume of 435,603. The business's fifty day moving average price is $19.27 and its two-hundred day moving average price is $21.86. The firm has a market cap of $1.03 billion, a price-to-earnings ratio of -4.52 and a beta of 0.92. Bicycle Therapeutics plc has a 52-week low of $12.17 and a 52-week high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last issued its earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.04. The business had revenue of $2.68 million during the quarter, compared to analysts' expectations of $6.82 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The business's revenue for the quarter was down 50.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.26) EPS. Equities research analysts anticipate that Bicycle Therapeutics plc will post -3.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bicycle Therapeutics

Several large investors have recently modified their holdings of the business. Natixis Advisors LLC purchased a new position in Bicycle Therapeutics during the second quarter valued at approximately $261,000. TD Asset Management Inc increased its holdings in shares of Bicycle Therapeutics by 76.7% in the 2nd quarter. TD Asset Management Inc now owns 97,186 shares of the company's stock valued at $1,967,000 after acquiring an additional 42,200 shares during the period. Renaissance Technologies LLC raised its position in shares of Bicycle Therapeutics by 97.2% in the 2nd quarter. Renaissance Technologies LLC now owns 326,800 shares of the company's stock worth $6,614,000 after acquiring an additional 161,100 shares in the last quarter. L & S Advisors Inc raised its position in shares of Bicycle Therapeutics by 16.1% in the 2nd quarter. L & S Advisors Inc now owns 58,335 shares of the company's stock worth $1,181,000 after acquiring an additional 8,075 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Bicycle Therapeutics during the 2nd quarter worth $206,000. Institutional investors own 86.15% of the company's stock.

Analyst Upgrades and Downgrades

BCYC has been the topic of a number of analyst reports. B. Riley cut their price objective on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a "neutral" rating on the stock in a research report on Friday, December 13th. HC Wainwright reduced their price objective on shares of Bicycle Therapeutics from $55.00 to $33.00 and set a "buy" rating on the stock in a research report on Monday, December 16th. Needham & Company LLC restated a "buy" rating and set a $38.00 target price on shares of Bicycle Therapeutics in a research report on Thursday, October 31st. Stephens started coverage on Bicycle Therapeutics in a research note on Friday, November 8th. They set an "equal weight" rating and a $25.00 target price on the stock. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $35.00 price target on shares of Bicycle Therapeutics in a research note on Friday, November 1st. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Bicycle Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $35.25.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.